The Role of Ghrelin in Cancer Cachexia

Cancer Cachexia Clinical Trial

Official title:

The Role of Ghrelin in Cancer Cachexia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01505764
• Other study ID #: CLIN-013-08F
• Secondary ID: HT-ANAM-208
• Status: Terminated
• Phase: Phase 2
• Start date: June 2012
• Est. completion date: March 2016

Study information

• Verified date: June 2018
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer is often coupled with a condition called cachexia. In this condition, individuals continue to lose weight and lean body mass, which means their muscles are getting smaller and weaker. Studies have shown that cancer patients who are losing weight often are responding poorly to chemotherapy, are at greater risk of infection and have a reduced life expectancy. Also, people may not want to eat. To date, there are no approved treatments available for this condition.

This study is going to study the benefits of the use of the study drug, Anamorelin hydrochloride (HCl) in treatment or prevention of cachexia associated with cancer. Studies done before with the study drug have shown that the drug can help the cachectic condition. The purpose of this research study is to evaluate the effectiveness of Anamorelin HCl compared to placebo on body composition (amount of cell mass, fat, muscle, etc.) including measurements of body potassium and nitrogen stores.

In addition to the above, the study will also assess the effect of the study drug on handgrip strength, body weight, lean muscle mass, quality of life, appetite & food intake, certain blood markers, energy expenditure (the amount of energy participants burn), functional performance, safety and tolerability of Anamorelin HCl.

Description:

Subjects enrolled in the study will be randomly chosen to receive either Anamorelin HCL at a dose of 100 mg per day for 12 weeks or matching placebo. The chances of receiving anamorelin or placebo are 1 in 2. Which subject receives anamorelin or placebo will be decided at random. Neither the subject nor the study doctor will know which study drug the subject is receiving. The subject will be asked to visit the clinic at Day 1, Day 28, Day 56 and Day 84. There will also be a Day 112 follow-up visit and the medical records will be checked after that to see how the subjects are doing.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: March 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have incurable, histologically or cytologically documented Non-Small Cell Lung Cancer or Colo-rectal Cancer.

• Females and males at least 18 years of age.

• Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) unresectable Stage III or IV NSCLC and/or stage III or IV colorectal cancer (CRC) (not amenable to curative resection).

• Involuntary weight loss of 5% body weight over a period of 6 months.

• Eastern Cooperative Oncology Group (ECOG) performance status 2 at screening.

• Estimated life expectancy of greater than 4 months at the time of screening.

• Presence and functional use of both hands.

• Able to understand and comply with the procedures of the handgrip strength evaluation.

• If the patient is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 28 days following the last dose of study medication.

• Willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures.

Exclusion Criteria:

• Other forms of lung cancer.

• Women who are pregnant or breast-feeding.

• Obesity.

• Recent active excessive alcohol or illicit drug use current use of marijuana or history of marijuana use over the previous 6 months.

• Severe depression.

• Other causes of cachexia such as:

• Liver disease (AST or ALT > 3x normal levels)

• Renal failure (creatinine > 2.5 mg/dL)

• Untreated thyroid disease

• Class III-IV CHF

• AIDS

• Other cancer diagnosed within the past five years other than non-melanoma skin cancer and prostate cancer

• Severe COPD requiring use of home O2.

• Inability to increase food intake.

• Recent administration of highly emetogenic chemotherapy.

• Known HIV, active hepatitis B or C (with increased LFTs), or active tuberculosis.

• Patients who have received two prior regimens of cytotoxic chemotherapy and are undergoing, or planning to undergo, a third regimen of cytotoxic chemotherapy.

• Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to:

• Testosterone

• Androgenic compounds

• Megestrol acetate

• Methylphenidate

• Dronabinol

• Current use of steroids or history of use over the previous 6 months except as pre- and post-medications for chemotherapy administration.

• Patients unable to readily swallow oral tablets.

• An active, uncontrolled infection.

• Uncontrolled diabetes mellitus.

• Known or suspected brain metastases.

• Patients receiving strong CYP3A4 inhibitors.

• Patients receiving tube feedings or parenteral nutrition.

• Patients with any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements, including the inability to comply with handgrip strength determinations in both hands; for example, pre-existing neurological impairment.

• Previous exposure to Anamorelin HCl.

• Patients actively receiving a concurrent investigational agent, or any patients that have received an investigational agent within four weeks prior to randomization.

• Current use of diuretics or history of intermittent diuretic usage for any reason over the previous 3 months.

• History of claustrophobia.

• Cachexia deemed by the investigator to be solely due to chemo or radiation treatment

Related Conditions & MeSH terms

• Cachexia
• Cancer Cachexia

Intervention

Drug:
• Anamorelin HCl
100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
• Placebo
Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.

Locations

Country	Name	City	State
United States	Michael E. DeBakey VA Medical Center, Houston, TX	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
VA Office of Research and Development	Helsinn Therapeutics (U.S.), Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Body Potassium.	percentage change from baseline	day 84
Secondary	Lean Mass Measured by Densitometry.	lean body mass measured by DEXA. Percentage of change day 84-baseline.	day 84
Secondary	Muscle Strength as Measured by Grip Strength.	Dominant hand grip strength day 84 - percent change from baseline	day 84
Secondary	Body Weight.	percent change from day 84-baseline	day 84
Secondary	Quality of Life.	Quality of life as assessed using the FACIT-F Patient Reported Outcome assessments - percentage of change day 84-baseline	day 84
Secondary	Appetite.	Appetite measured by a visual analogue scale ASAS. Percentage of change day84-baseline	day 84
Secondary	Resting Energy Expenditure.	% change between day 84 and baseline	day 84
Secondary	Functional Performance.	Functional performance using stair-climbing power day 84 percent change from baseline	day 84
Secondary	Body Composition.	Body composition as measured by Total body nitrogen. Percentage of change day 84-baseline	day 84
Secondary	Stair Climbing Power	Percent change from baseline	day 84
Secondary	1-repetition Max. Strength	leg extension - percentage of change day 84 to baseline	day 84
Secondary	Food Diary Calorie Count	change between day 84 and baseline	day 84